Shenzhen
Meridan ReportShenzhen: Hardware capital of the world

Advertisement · Why this ad?

Health

Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

Marcus Chen
Managing Editor · Tuesday, November 3, 2026 at 8:00 AM · 1 min read
Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial — Shenzhen Health news

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer. The median progression-free survival (PFS) – the length of...

Up nextNew York state reports first measles-linked death in over 30 yearsHealth · 1 min read
#wellness
You're offline — showing the last loaded page